Alembic Pharmaceuticals Ltd
APLLTDAlembic Pharmaceuticals Ltd
APLLTD
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 38.33 | 4.90 | 0.92% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 12 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,173.11 | 3,107.17 | 3,137.84 | 3,944.06 | 4,610.69 | 5,480.42 | 5,361.53 | 5,655.36 | 6,256.93 | 6,256.94 | ||||||||||
Raw Materials | 877.07 | 928.05 | 927.62 | 1,084.97 | 1,249.98 | 1,451.27 | 1,489.61 | 1,630.17 | 1,857.92 | 5,296.24 | ||||||||||
| Power & Fuel Cost | 58.89 | 64.20 | 70.35 | 88.86 | 102.40 | 118.72 | 120.84 | 151.54 | 173.37 | |||||||||||
| Employee Cost | 472.85 | 558.83 | 622.81 | 746.69 | 906.44 | 1,051.17 | 1,133.00 | 1,169.13 | 1,446.29 | |||||||||||
| Selling & Administrative Expenses | 507.40 | 791.13 | 700.51 | 961.11 | 913.65 | 1,104.03 | 1,354.87 | 1,474.00 | 1,543.70 | |||||||||||
| Operating & Other expenses | 243.09 | 147.67 | 166.42 | 179.47 | 253.92 | 187.65 | 333.31 | 550.33 | 274.96 | |||||||||||
EBITDA | 1,013.81 | 617.29 | 650.13 | 882.96 | 1,184.30 | 1,567.58 | 929.90 | 680.19 | 960.69 | 960.70 | ||||||||||
| Depreciation/Amortization | 72.21 | 82.97 | 105.46 | 115.23 | 157.32 | 183.48 | 286.78 | 275.43 | 272.67 | 272.67 | ||||||||||
| PBIT | 941.60 | 534.32 | 544.67 | 767.73 | 1,026.98 | 1,384.10 | 643.12 | 404.76 | 688.02 | 688.03 | ||||||||||
| Interest & Other Items | 5.43 | 5.23 | 3.40 | 18.41 | 27.16 | 16.02 | 17.73 | 50.17 | 56.19 | 56.19 | ||||||||||
| PBT | 936.17 | 529.09 | 541.27 | 749.32 | 999.82 | 1,368.08 | 625.39 | 354.59 | 631.83 | 631.84 | ||||||||||
| Taxes & Other Items | 216.12 | 125.93 | 128.64 | 164.95 | 171.00 | 221.58 | 104.45 | 12.60 | 16.01 | 16.02 | ||||||||||
| Net Income | 720.05 | 403.16 | 412.63 | 584.37 | 828.82 | 1,146.50 | 520.94 | 341.99 | 615.82 | 615.82 | ||||||||||
| EPS | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 59.55 | 26.50 | 17.40 | 31.33 | 31.33 | ||||||||||
| DPS | 3.50 | 4.00 | 4.00 | 5.50 | 10.00 | 14.00 | 10.00 | 8.00 | 11.00 | 8.00 | ||||||||||
| Payout ratio | 0.09 | 0.19 | 0.18 | 0.18 | 0.23 | 0.24 | 0.38 | 0.46 | 0.35 | 0.26 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alembic Pharmaceuticals Ltd | 38.33 | 4.90 | 0.92% |
| Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
| Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
| Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare APLLTD with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Alembic Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Kotak Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.2779% | Percentage of the fund’s portfolio invested in the stock 1.81% | Change in the portfolio weight of the stock over the last 3 months -0.64% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/83 (-10) |
DSP Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1007% | Percentage of the fund’s portfolio invested in the stock 1.47% | Change in the portfolio weight of the stock over the last 3 months -0.51% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/66 (-9) |
DSP Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5286% | Percentage of the fund’s portfolio invested in the stock 5.03% | Change in the portfolio weight of the stock over the last 3 months -0.89% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/32 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
APLLTD has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.92%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹9.16 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 15, 2024
Dividend/Share
₹11.00
Ex DateEx Date
Jul 15, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateAug 17, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Aug 17, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Dividend/Share
₹14.00
Ex DateEx Date
Jul 19, 2021
Cash Dividend
Ex DateEx DateMar 16, 2020
Dividend/Share
₹3.00
Ex DateEx Date
Mar 16, 2020
Alembic Pharma’s Panelav unit successfully completes USFDA inspection
Alembic Pharmaceuticals has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid Formulation Facility (F-I) located at Panelav. This was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from 17 July 2024 to 26 July 2024. Powered by Capital Market - Live
Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 August 2024.Powered by Capital Market - Live
Alembic Pharma hits record high on USFDA nod for anti psychotic drug
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Prolixin tablets of Apothecon Inc. Fluphenazine hydrochloride tablets, USP are indicated in the management of manifestations of psychotic disorders. Alembic has a cumulative total of 210 ANDA approvals (182 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world. The company reported 16.78% increase in consolidated net profit to Rs 178.21 crore on 7.85% rise in revenue from operations to Rs 1,516.98 in Q4 FY24 over Q4 FY23. The scrip hit an all time high at Rs 1,192.75 in today's intra-day session. Powered by Capital Market - Live
Technical Breakout Stocks: Alembic Pharma, Dr Lal PathLabs and Zydus Wellness hit 52-week highs; what should traders do? - Market Roundup
Just Dial, Alembic Pharmaceuticals and Hatsun Agro Product: Three stocks that outperformed in the week ended July 19
Tata Teleservices (Maharashtra) Ltd, Sunteck Realty Ltd, Chennai Petroleum Corporation Ltd, Godawari Power & Ispat Ltd are among the other stocks to see a surge in volumes on NSE today, 16 July 2024.Alembic Pharmaceuticals Ltd clocked volume of 34.55 lakh shares by 14:14 IST on NSE, a 12.94 times surge over two-week average daily volume of 2.67 lakh shares. The stock gained 11.82% to Rs.1,097.90. Volumes stood at 1.86 lakh shares in the last session.Tata Teleservices (Maharashtra) Ltd saw volume of 349.62 lakh shares by 14:14 IST on NSE, a 10.03 fold spurt over two-week average daily volume of 34.85 lakh shares. The stock increased 6.16% to Rs.81.85. Volumes stood at 64.28 lakh shares in the last session.Sunteck Realty Ltd clocked volume of 81.02 lakh shares by 14:14 IST on NSE, a 9.72 times surge over two-week average daily volume of 8.33 lakh shares. The stock gained 4.86% to Rs.637.65. Volumes stood at 18.6 lakh shares in the last session.Chennai Petroleum Corporation Ltd clocked volume of 171.29 lakh shares by 14:14 IST on NSE, a 8.67 times surge over two-week average daily volume of 19.77 lakh shares. The stock gained 15.05% to Rs.1,248.00. Volumes stood at 25.68 lakh shares in the last session.Godawari Power & Ispat Ltd clocked volume of 23.02 lakh shares by 14:14 IST on NSE, a 6.55 times surge over two-week average daily volume of 3.51 lakh shares. The stock gained 3.70% to Rs.1,158.40. Volumes stood at 1.72 lakh shares in the last session.Powered by Capital Market - Live
Alembic Pharma gets tentative USFDA nod for Selexipag injection
Stocks that will see action today: 15 July 2024
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.67%, vs industry avg of 8.96%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.74% to 1.7%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 1.05%, vs industry avg of 15.15%